Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- OTC NEWS IN BRRIEF
April 12, 2004
- Informed Choice Better than Informed Consent: JPMA Consumer Survey
April 12, 2004
- Japanese Healthcare Q&A (7)
April 12, 2004
- BUSINESS NEWS IN BRIEF -1-
April 12, 2004
- DIAGNOSTIC NEWS IN BRIEF
April 12, 2004
- BUSINESS NEWS IN BRIEF -2-
April 12, 2004
- WORLD NEWS IN BREIF
April 12, 2004
- Harnal, Lipitor, Micardis Show Continued Growth: Yamanouchi
April 12, 2004
- 57% of Drug Makers Asked to Change Products' Appearance to Prevent Accidents
April 12, 2004
- NEW PRODUCTS
April 12, 2004
- More than 30% of Drug Companies Not Compliant with GPMSP: Korosho Survey
April 12, 2004
- METI to Promote Training of Human Resources for Biotech Industry
April 12, 2004
- Gov't Approves 3-Year Plan for Regulatory Reform
April 12, 2004
- Medical Institutions Should Disclose Accidents: Dr Sakaguchi
April 12, 2004
- Dr Sakaguchi Sees Domestic, Foreign Drug Price Gap as "Major Problem"
April 12, 2004
- Insurance Coverage Requested for Candesartan as CHF Treatment
April 12, 2004
- CORPORATE ROUNDUP NEWS IN BRIEF
April 5, 2004
- Kyowa Hakko to License "Potelligent" Technology to US Companies
April 5, 2004
- Somusho Asks Korosho to Simplify Approval Modification Procedure
April 5, 2004
- BULLETIN
April 5, 2004
ページ
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…